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Multiple endpoints are increasingly used in clinical trials. The significance of some of
these clinical trials is established if at least r null hypotheses are rejected among m
that are simultaneously tested. The usual approach in multiple hypothesis testing is to
control the family-wise error rate, which is defined as the probability that at least one
type-I error is made. More recently, the q-generalized family-wise error rate has been
introduced to control the probability of making at least q false rejections. For
procedures controlling this global type-I error rate, we define a type-II r-generalized
family-wise error rate, which is directly related to the r-power defined as the
probability of rejecting at least r false null hypotheses. We obtain very general power
formulas that can be used to compute the sample size for single-step and step-wise
procedures. These are implemented in our R package rPowerSampleSize available on
the CRAN, making them directly available to end users. Complexities of the formulas
are presented to gain insight into computation time issues. Comparison with Monte
Carlo strategy is also presented. We compute sample sizes for two clinical trials
involving multiple endpoints: one designed to investigate the effectiveness of a drug
against acute heart failure and the other for the immunogenicity of a vaccine strategy
against pneumococcus. Copyright © 2016 John Wiley & Sons, Ltd.
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